Gyre Therapeutics Inc.
Organization details
- Legal name
- Gyre Therapeutics Inc.
- Former names
- Catalyst Biosciences, INC. Targacept Inc
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- GYRE
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001124105
- EIN
- 56-2020050
Board of directors
-
Andrea Hunt · DirectorSince 2023
-
Augustine Lawlor · DirectorSince 2023
-
Charles C. Wu · Director · Chief Executive OfficerSince 2023
-
Claire Weston · DirectorSince 2026
-
Dan Weng · DirectorSince 2025
-
David M. Epstein · DirectorSince 2024
-
Gordon Carmichael · DirectorSince 2023
-
Han Ying · Director · Chief Executive OfficerSince 2023
-
Maxwell Kirkby · DirectorSince 2026
-
Nassim Usman · Director · President & CEOSince 2023
-
Ping Zhang · DirectorSince 2025
-
Renate Parry · DirectorSince 2023
-
Rodney L. Nussbaum · DirectorSince 2024
-
Songjiang Ma · Director · PresidentSince 2023
-
Thomas Wilson Eastling · DirectorSince 2022
-
Ying Luo · Director · Chief Executive OfficerSince 2022
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 35% of the scoring weight is on file.
- Revenue growth 20%
- 60
- Earnings growth 15%
- 15
4.5% a year in revenue
-12.6% a year in earnings per share
35% of the scoring weight is on file. Figures cover December 2022 – December 2025.
Director election results
Annual meeting of August 29, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
97.7%
-
97.8%
Board connections
2 of this board's directors also sit on 2 other boards. 2 are in the same sector.
-
Black Diamond Therapeutics Inc. Same sectorvia David M. Epstein
-
PRF Technologies Ltd. Same sectorvia Augustine Lawlor
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $952,874
- 18 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 18, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +3,000 | $0.75 | $2,250 |
| Jun 18, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −3,000 | $6.35 | $19,050 |
| Jun 11, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +2,800 | $0.75 | $2,100 |
| Jun 11, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −2,800 | $6.17 | $17,276 |
| Jun 10, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +5,000 | $0.75 | $3,750 |
| Jun 10, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +6,418 | $0.75 | $4,814 |
| Jun 10, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −5,000 | $6.24 | $31,200 |
| Jun 10, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −6,418 | $6.21 | $39,856 |
| Jun 9, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +3,000 | $0.75 | $2,250 |
| Jun 9, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +14,500 | $0.75 | $10,875 |
| Jun 9, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −3,000 | $6.15 | $18,450 |
| Jun 9, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −14,500 | $6.14 | $89,030 |
| Jun 5, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +15,401 | $0.75 | $11,551 |
| Jun 5, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Open-market sale | −15,401 | $6.40 | $98,566 |
| Jun 4, 2026 | Ye Weiguo Officer (Chief Operating Officer) | Option exercise | +19,575 | $0.75 | $14,681 |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about Gyre Therapeutics Inc.
Who is the CEO of Gyre Therapeutics Inc.?
Ying Luo has been Gyre Therapeutics Inc.'s Chief Executive Officer since May 2026.
How many directors are on Gyre Therapeutics Inc.'s board?
Gyre Therapeutics Inc.'s board has 16 directors: Andrea Hunt, Augustine Lawlor, Charles C. Wu, Claire Weston, Dan Weng, David M. Epstein, Gordon Carmichael, Han Ying, Maxwell Kirkby, Nassim Usman and 6 others.
Are Gyre Therapeutics Inc. insiders buying or selling shares?
Over the last 12 months, Gyre Therapeutics Inc. insiders made no open-market purchases and sold $952,874 of shares in 18 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="gyre-therapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.